Cleveland Clinic ACO takes on downside risk with move to Track 1+ model: 4 things to know

Cleveland Clinic Medicare ACO will shoulder more downside risk after becoming a Track 1+ ACO this year.

Advertisement

Here are four things to know about the change.

1. Under the new Track 1+ model, Cleveland Clinic Medicare ACO qualifies as an Advanced Payment Model under the Medicare Access and CHIP Reauthorization Act. 

2. As a Track 1+ ACO, Cleveland Clinic Medicare ACO will assume limited performance-based downside risk if it doesn’t reach a specific savings benchmark. The downside risk is a fixed 30 percent loss-sharing rate.

3. However, by assuming greater risk, Cleveland Clinic Medicare ACO will also be able to share higher savings based on quality performance — up to 50 percent. If the health system meets MACRA’s quality reporting requirements, Cleveland Clinic could see greater Medicare reimbursement for physician services beginning in 2019. 

4. Cleveland Clinic Medicare ACO, which manages 105,000 beneficiaries, achieved $42.2 million in savings in 2016, up 24.5 percent from the year prior.

More articles on ACOs:
17 ACOs join CMS’ Next Generation model
Trinity Health of New England, Aetna partner for ACO product: 3 notes
Arizona Care Network ACO, Cigna to offer joint health plan: 4 things to know

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Rethinking Safety and Security in the Healthcare Environment

Thursday, July 23
1:00 PM - 2:00 PM CDT

Presenters: Jon Share, AxonDan Snyder, Advocate HealthKeith Hunter, Wellstar

Advertisement

Next Up in Care Coordination

Advertisement

Comments are closed.